Literature DB >> 11803287

A case of primary cutaneous CD56+, TdT+, CD4+, blastic NK-cell lymphoma in a 19-year-old woman.

Sung Eun Chang1, Hae Jung Choi, Jooryung Huh, Jee Ho Choi, Kyung Jeh Sung, Kee Chan Moon, Jai Kyoung Koh.   

Abstract

The classification of blastic or blastoid natural killer (NK)-cell lymphoma is controversial. Reports of primary cutaneous blastic CD56+ NK-cell lymphoma are rare, which necessitates further clinicopathologic definition of this type of lymphoma. Most CD56+ lymphomas display angiocentric histologic features, especially in Asian patients, and these are mostly associated with the presence of Epstein-Barr virus (EBV) genome and with an aggressive clinical course. We report on a young woman with a primary cutaneous blastic NK lymphoma which showed no angiocentric features but showed an unusual immunophenotype; CD56+, TdT+, CD4+, EBV-, and germline configuration of T-cell receptor gene. This unusual lymphoblastic lymphoma seems to have an immature or progenitor NK cell lineage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11803287     DOI: 10.1097/00000372-200202000-00015

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  3 in total

1.  CD4-/CD56+/CD123+ Hematodermic Neoplasm Showing Early Liver Metastasis.

Authors:  Kyu-Won Choi; Ki-Yeol Lee; Yeong-Kyu Lee; Bon-Seok Ku; Hong-Seok Kim; Young-Hun Kim; Ki-Ho Kim
Journal:  Ann Dermatol       Date:  2010-05-18       Impact factor: 1.444

2.  CD4+CD56+ lineage negative hematopoietic neoplasm: so called blastic NK cell lymphoma.

Authors:  Yoonjung Kim; Mi Seon Kang; Chan Whan Kim; Rohyun Sung; Young H Ko
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

Review 3.  What is CD4+CD56+ malignancy and how should it be treated?

Authors:  P Reimer; T Rüdiger; D Kraemer; V Kunzmann; F Weissinger; A Zettl; H Konrad Müller-Hermelink; M Wilhelm
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.